287 related articles for article (PubMed ID: 23005040)
21. Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes.
Wu X; Liu W; Tian Y; Xiao M; Wu Y; Li C
Acta Haematol; 2011; 125(4):179-85. PubMed ID: 21212658
[TBL] [Abstract][Full Text] [Related]
22. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Wang YL; Han LX; Xu WR; Wu CY
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):74-81. PubMed ID: 19196380
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
[TBL] [Abstract][Full Text] [Related]
24. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome.
Qian J; Chen XX; Qian W; Yang J; Wen XM; Ma JC; Deng ZQ; Qian Z; Zhang YY; Lin J
Clin Chem Lab Med; 2014 Dec; 52(12):1859-65. PubMed ID: 25153418
[TBL] [Abstract][Full Text] [Related]
25. [Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].
Zhang YZ; Zhao DD; Zhao WP; Zhao HF; Zhao ZG; Wang YF; Wu XX; Han XP; Da WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):108-12. PubMed ID: 22730659
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of hypermethylation of DLC-1 gene in myelodysplastic syndrome patients and effects of decitabine on DLC-1 gene expression].
Fu HY; Zhou HR; Yan JG; Chen CJ; Shen JZ
Zhonghua Yi Xue Za Zhi; 2017 Feb; 97(6):412-417. PubMed ID: 28219126
[No Abstract] [Full Text] [Related]
27. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
28. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
[TBL] [Abstract][Full Text] [Related]
29. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
30. [Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine].
Deng YF; Zhang L; Zhang XQ; Hu MQ; Dai D; Zhang XZ; Xu YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1144-8. PubMed ID: 23114136
[TBL] [Abstract][Full Text] [Related]
31. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
32. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
33. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
36. Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes.
Papageorgiou SG; Pappa V; Papageorgiou E; Tsirigotis P; Kontsioti F; Panani A; Dervenoulas J; Economopoulos T
Eur J Haematol; 2005 Sep; 75(3):193-8. PubMed ID: 16104874
[TBL] [Abstract][Full Text] [Related]
37. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
[TBL] [Abstract][Full Text] [Related]
39. Semi-quantitative study of calcitonin gene methylation in myelodysplastic syndrome.
Wu S; Xie G; Bai R; Wang Y; Zhu P
Chin Med J (Engl); 1998 Aug; 111(8):690-3. PubMed ID: 11245020
[TBL] [Abstract][Full Text] [Related]
40. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
